We next assayed CSF Total Tau peptide concentrations in 11 Alzheimer’s Disease CSF samples across two independent analytical runs (n = 4 replicates) to understand the precision of our LC-MS assay in diseased CSF (Table 2). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.